AAOI Stock Falls Sharply on $600M At-the-Market Offering Announcement
The agreement does not specify how the proceeds would be used.
Already have an account? Sign in.
The agreement does not specify how the proceeds would be used.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.